Pleiotropy and Mechanism of Peripheral Nerve Related Genes in the Progression of Amyotrophic Lateral Sclerosis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04953494|
Recruitment Status : Not yet recruiting
First Posted : July 8, 2021
Last Update Posted : July 8, 2021
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment|
|Amyotrophic Lateral Sclerosis||Diagnostic Test: Patient information collection, exon sequencing and follow-up.|
|Study Type :||Observational|
|Estimated Enrollment :||300 participants|
|Official Title:||Pleiotropy and Mechanism of Peripheral Nerve Related Genes in the Progression of Amyotrophic Lateral Sclerosis|
|Estimated Study Start Date :||August 1, 2021|
|Estimated Primary Completion Date :||August 31, 2021|
|Estimated Study Completion Date :||December 31, 2022|
|Amyotrophic lateral sclerosis patients group||
Diagnostic Test: Patient information collection, exon sequencing and follow-up.
Clinical baseline data, disease characteristics, auxiliary examination results, EMG examination results, drug use and other information were collected. 4-6ml peripheral blood was collected for exon sequencing. The patients were followed up every three months by a specialist in the form of outpatient or telephone.
- death [ Time Frame: until the patient dies, usually 1-10 years after diagnosis. ]patients' death
- invasive breathing [ Time Frame: until the patient has invasive breathing, usually 1-10 years after diagnosis. ]The patient uses a ventilator to maintain breathing
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||Child, Adult, Older Adult|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
|Sampling Method:||Non-Probability Sample|
- Since February 2021, he has been in the Department of Neurology, the Third Hospital of Beijing Medical University. He was diagnosed amyotrophic lateral sclerosis according to the revised EI Escorial diagnostic criteria of 2004 edition, and the patients within one year of onset.
- Informed consent has been signed.
- Patients with ALS like syndrome caused by autoimmune diseases, paraneoplastic syndrome and simple demyelinating lesions were excluded.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04953494
|Peking University Third Hospital|
|Beijing, Beijing, China, 100098|
|Responsible Party:||Peking University Third Hospital|
|Other Study ID Numbers:||
|First Posted:||July 8, 2021 Key Record Dates|
|Last Update Posted:||July 8, 2021|
|Last Verified:||July 2021|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
Motor Neuron Disease
Amyotrophic Lateral Sclerosis
Nervous System Diseases
Spinal Cord Diseases
Central Nervous System Diseases